Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 6
Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2
Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.
Video Player is loading.
- Briefly discuss your general treatment approach in patients with EGFR-mutant NSCLC.
- What treatment options are available? What is the standard of care in this setting?
- What factors do you consider in guiding treatment selection?
- Please review key efficacy and safety data from FLAURA2 evaluating 1L osimertinib with chemotherapy in patients with EGFR-mutant advanced NSCLC.(Janne, et al. WCLC 2023. Abstract PL03.13; Planchard, et al. ESMO 2023. Abstract LBA68)
- What implications may these findings have on clinical practice?
Related Content:
